Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A collaborative research team from the Universities of Oxford and Cambridge, co-led by Department of Physiology, Anatomy & Genetics Associate Professor Ana Domingos, have developed a new weight-loss amphetamine that could potentially avoid the harmful side effects of traditional treatments.

© CireniaSketches

Obesity is a major health issue across the world and is implicated in many serious health conditions such as diabetes, heart disease and cancer. Despite being officially declared a chronic disease, there are very few long-lasting and cost-effective treatments for obesity. Historically, amphetamine (AMPH) class drugs have been some of the most popular anti-obesity drugs to be prescribed and are widely considered to be the most effective while also being among the cheapest to produce. They work in the brain to reduce appetite and increase locomotion or stamina. However, these drugs are also known for strongly activating the sympathetic nervous system, the peripheral part of the nervous system known to accelerate the heart rate, constrict blood vessels and raise blood pressure. Consequently, they can present side effects such as dangerously increased heart rate and hypertension.  

A research team led by Department of Physiology, Anatomy & Genetics Associate Professor Ana Domingos and Dr Gonçalo Bernardes (University of Cambridge) suspected that the cardiac side effects of amphetamines could originate in the brain. If this was the case, they hypothesised that if they could design a drug that did not pass the blood-brain barrier, they could avoid these unwanted outcomes, while perhaps retaining an anti-obesity action. In a new paper published in Cell Metabolism, the team have shown that the cardiac side effects of AMPH do indeed originate in the brain and have presented a modified amphetamine that does not enter the brain while avoiding its known side effects.

Read the full story on the Department of Physiology, Anatomy & Genetics website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.